Meeting
2012 ASCO Annual Meeting
Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs).
Authors
Meir Wetzler
Roswell Park Cancer Institute, Buffalo, NY
Meir Wetzler , Hagop Kantarjian , Franck E. Nicolini , Jeffrey Howard Lipton , Luke Paul Akard , Michele Baccarani , Adam Craig , Peter D. Brown , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00375219, NCT00462943
Citation
J Clin Oncol 30, 2012 (suppl; abstr 6604)
DOI
10.1200/jco.2012.30.15_suppl.6604
Abstract #
6604
Poster Bd #
22G
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).
First Author: Franck E. Nicolini
First Author: Rüdiger Hehlmann
Poster
2011 ASCO Annual Meeting
Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.
First Author: M. Talpaz
Poster
2021 ASCO Annual Meeting
Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.
First Author: Niven Mehra